SG11201700882XA - Heterobicyclic compounds and their use for the treatment of tuberculosis - Google Patents

Heterobicyclic compounds and their use for the treatment of tuberculosis

Info

Publication number
SG11201700882XA
SG11201700882XA SG11201700882XA SG11201700882XA SG11201700882XA SG 11201700882X A SG11201700882X A SG 11201700882XA SG 11201700882X A SG11201700882X A SG 11201700882XA SG 11201700882X A SG11201700882X A SG 11201700882XA SG 11201700882X A SG11201700882X A SG 11201700882XA
Authority
SG
Singapore
Prior art keywords
tuberculosis
treatment
heterobicyclic compounds
heterobicyclic
compounds
Prior art date
Application number
SG11201700882XA
Other languages
English (en)
Inventor
Hiroshi Shimizu
Yoshikazu Kawano
Shunpei Ishikawa
Yukitaka Uematsu
Toshio Shinohara
Motohiro Itotani
Yoshikazu Haraguchi
Isao Takemura
Atsunori Kaneshige
Yuya Nakai
Norimitsu Hariguchi
Yohei Hayashi
Makoto Matsumoto
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG11201700882XA publication Critical patent/SG11201700882XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
SG11201700882XA 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis SG11201700882XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014174528 2014-08-28
PCT/JP2015/004371 WO2016031255A1 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Publications (1)

Publication Number Publication Date
SG11201700882XA true SG11201700882XA (en) 2017-03-30

Family

ID=54105947

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700882XA SG11201700882XA (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Country Status (29)

Country Link
US (2) US10053446B2 (pl)
EP (1) EP3186240B9 (pl)
JP (1) JP6625612B2 (pl)
KR (1) KR102418413B1 (pl)
CN (1) CN106795117B (pl)
AP (1) AP2017009788A0 (pl)
AR (1) AR101704A1 (pl)
AU (1) AU2015307873B2 (pl)
BR (1) BR112017003231B1 (pl)
CA (1) CA2959478C (pl)
CY (1) CY1122286T1 (pl)
DK (1) DK3186240T3 (pl)
EA (1) EA038414B1 (pl)
ES (1) ES2743788T3 (pl)
HR (1) HRP20191486T2 (pl)
HU (1) HUE045025T2 (pl)
IL (1) IL250484B (pl)
LT (1) LT3186240T (pl)
MX (1) MX2017002312A (pl)
MY (1) MY189098A (pl)
NZ (1) NZ729064A (pl)
PH (1) PH12017500290A1 (pl)
PL (1) PL3186240T3 (pl)
PT (1) PT3186240T (pl)
SG (1) SG11201700882XA (pl)
SI (1) SI3186240T1 (pl)
TW (1) TWI687409B (pl)
WO (1) WO2016031255A1 (pl)
ZA (1) ZA201700916B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
US10851079B2 (en) 2016-02-26 2020-12-01 Otsuka Pharmaceutical Co., Ltd. Piperidine derivative
US20210292333A1 (en) 2018-06-15 2021-09-23 Cadila Healthcare Limited Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria
JP2023085582A (ja) * 2020-05-11 2023-06-21 大塚製薬株式会社 ジヒドロキノリノン化合物の共結晶
KR20220022877A (ko) * 2020-08-19 2022-02-28 주식회사 미토이뮨테라퓨틱스 Mabc-R 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN116102537A (zh) * 2021-11-10 2023-05-12 四川大学 一种喹啉酮类衍生物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
TWI347946B (en) 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
KR100851802B1 (ko) * 2003-10-31 2008-08-13 오쓰까 세이야꾸 가부시키가이샤 결핵의 치료를 위한2,3-디히드로-6-니트로이미다조[2,1-b]옥사졸 화합물
JP4761756B2 (ja) 2003-10-31 2011-08-31 大塚製薬株式会社 2,3−ジヒドロイミダゾ[2,1−b]オキサゾ−ル化合物
UA91822C2 (ru) * 2003-10-31 2010-09-10 Оцука Фармасьютикел Ко., Лтд. СОЕДИНЕНИЕ 2,3-ДИГИДРО-6-НИТРОИМИДАЗО[2,1-b]ОКСАЗОЛА ДЛЯ ЛЕЧЕНИЯ ТУБЕРКУЛЕЗА
CN101006076B (zh) * 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
US8293734B2 (en) 2009-07-31 2012-10-23 Global Alliance For Tb Drug Development Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
JP5916739B2 (ja) 2011-04-15 2016-05-11 大塚製薬株式会社 6,7−ジヒドロイミダゾ[2,1−b][1,3]オキサジン化合物
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
US10851079B2 (en) * 2016-02-26 2020-12-01 Otsuka Pharmaceutical Co., Ltd. Piperidine derivative

Also Published As

Publication number Publication date
KR102418413B1 (ko) 2022-07-06
HUE045025T2 (hu) 2019-12-30
HRP20191486T1 (hr) 2019-11-15
US20170253576A1 (en) 2017-09-07
DK3186240T3 (da) 2019-08-26
PL3186240T3 (pl) 2020-03-31
PT3186240T (pt) 2019-09-06
TWI687409B (zh) 2020-03-11
EP3186240B9 (en) 2019-12-04
IL250484B (en) 2020-04-30
CA2959478C (en) 2023-09-26
MX2017002312A (es) 2017-05-08
AU2015307873A1 (en) 2017-03-09
CN106795117B (zh) 2020-06-26
LT3186240T (lt) 2019-09-10
US20180312488A1 (en) 2018-11-01
KR20170043644A (ko) 2017-04-21
AR101704A1 (es) 2017-01-04
AP2017009788A0 (en) 2017-02-28
HRP20191486T2 (hr) 2021-09-17
EP3186240B1 (en) 2019-06-12
NZ729064A (en) 2022-09-30
US10053446B2 (en) 2018-08-21
SI3186240T1 (sl) 2019-10-30
WO2016031255A1 (en) 2016-03-03
AU2015307873B2 (en) 2020-01-16
ZA201700916B (en) 2019-06-26
CA2959478A1 (en) 2016-03-03
MY189098A (en) 2022-01-25
JP6625612B2 (ja) 2019-12-25
ES2743788T3 (es) 2020-02-20
EA038414B1 (ru) 2021-08-25
PH12017500290A1 (en) 2017-06-28
TW201609658A (zh) 2016-03-16
EP3186240A1 (en) 2017-07-05
US10464926B2 (en) 2019-11-05
BR112017003231A2 (pt) 2017-11-28
BR112017003231B1 (pt) 2022-10-11
CY1122286T1 (el) 2021-01-27
EA201790464A1 (ru) 2017-06-30
JP2017525697A (ja) 2017-09-07
IL250484A0 (en) 2017-03-30
CN106795117A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
HK1243073A1 (zh) 治療性化合物及其用途
IL247841A0 (en) Heterocyclic compounds for use in the treatment of disorders mediated by pi3k gamma
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
GB201403093D0 (en) Therapeutic compounds and their use
IL251988A0 (en) Compounds acting on glycans and methods of using them
HRP20191486T1 (hr) Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze
HUE050761T2 (hu) Vegyületek és alkalmazási eljárások
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
IL251904A0 (en) Epilimod for use in the treatment of melanoma
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
GB201403697D0 (en) Compounds and methods of use
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use